Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous EBV-CTL transduced with vector SFG-CNA12
- Development stage
- Unknown
- Lead developer
- University College London
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous EBV-CTL transduced with vector SFG-CNA12 is an investigational Advanced Therapy Investigational Medicinal Product (ATIMP) developed by University College London for the treatment of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD). The therapy consists of a patient's own EBV-specific cytotoxic T-lymphocytes (CTLs) that have been retrovirally transduced with the SFG vector to express a mutant form of calcineurin A (CNA12). This genetic modification renders the T-cells resistant to the immunosuppressive effects of tacrolimus (FK506), a calcineurin inhibitor commonly administered to solid organ transplant recipients. By maintaining their effector function in the presence of tacrolimus, these engineered CTLs can specifically target and eliminate EBV-infected B-cells that drive PTLD without requiring the reduction of necessary immunosuppression.
- Other names
- tacrolimus-resistant autologous EBV-specific cytotoxic T-cellsCNA12-transduced EBV-CTLCNA-12-transduced EBV-CTLCNA 12-transduced EBV-CTLautologous EBV-CTL transduced with vector SFG-CNA12
02
Targets
PPP3CA (Protein phosphatase 3 catalytic subunit alpha)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous EBV-CTL transduced with vector SFG-CNA12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous EBV-CTL transduced with vector SFG-CNA12.